TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04202094

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scrotum ultrasound
Description: A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scrotum ultrasound
Description: A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semen analysis
Description: A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semen analysis
Description: A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
Study: NCT04589988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removing Environmental Barriers to Independent Living (REBIL)
Description: REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Attentional Control
Description: The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
Study: NCT02511769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WEB-MAP Educational Control Group
Description: OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
Study: NCT03952312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncotool Intervention (symptom reporting + TKI education)
Description: OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncotool Control (health information)
Description: OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study: NCT03151525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: AZA treatment after IFX withdrawal for maintenance of remission

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: IFX treatment for maintenance of remission
Study: NCT03660904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: home made vitrification & thawing kit
Description: home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: commercially made vitrification & thawing kit
Description: commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
Study: NCT04660903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat cell transplantation
Description: Up to 75 ml of fatty tissue mixture fluid
Study: NCT02511769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-MAP CBT
Description: Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
Study: NCT04573075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Description: a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
Study: NCT03044873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
Study: NCT01752517

Intervention type: DRUG
Intervention: NI group
Description: vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
Study: NCT04573075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: loop ileostomy
Description: a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
Study: NCT01746667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in vivo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Study: NCT01219244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: 6 months of caloric restriction (15 %)
Study: NCT04573075

Intervention type: PROCEDURE
Group type: OTHER
Intervention: no outlet
Description: no further intervention is used after colorectal resection and forming of a primary anastomosis
Study: NCT03748212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D935 Cap. 1T
Description: single oral administration under fed condition
Study: NCT01219244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: 6 months of omega-3 supplementation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resveratrol supplementation
Description: 6 months of resveratrol supplementation
Study: NCT03173534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN
Description: WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement
Study: NCT04163679

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal Preparation
Description: One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Preparation
Description: One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick.
Study: NCT05696860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography Monitoring
Description: Capnography monitoring
Study: NCT03237871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message survey and informational text messages
Description: Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
Study: NCT00911742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD
Description: 1 Tramadol Contramid OAD 200 mg tablet as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytram
Description: 1 Zytram 200 mg tablet as a single dose
Study: NCT03748212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-385 Tab. 1T
Description: single oral administration under fed condition
Study: NCT02902601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 600 mg
Description: Participants will receive JNJ-54175446, 600 mg as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 600 mg
Description: Participants will receive JNJ-54175446, 600 mg as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 150 mg
Description: Participants will receive JNJ-54175446, 150 mg as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446, 150 mg
Description: Participants will receive JNJ-54175446, 150 mg as an oral suspension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-54175446

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to JNJ-54175446
Study: NCT03531060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL790
Description: IRL790 capsule 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT04835116

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.
Description: Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.
Description: Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.
Description: Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.
Description: Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
Study: NCT01219244

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of placebo intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2nd step: intervention + physical / cognitive training
Description: most effective dietary intervention plus physical and cognitive training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2nd step: intervention + control
Description: most effective dietary intervention plus control
Study: NCT03635190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orbital Circumferential Atherectomy
Description: Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
Study: NCT01563588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietaty education, physical training, physiotherapy and SPA cares
Description: 12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
Study: NCT00704249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine
Description: Full-dose nevirapine from baseline (200 mg bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine
Description: Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
Study: NCT03605134

Intervention type: DIAGNOSTIC_TEST
Intervention: level of cardiac troponin
Description: blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: diastolic function assessment
Description: transthoracic echocardiography
Study: NCT00978575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferricarboxymaltose
Description: Single dose of maximum 1000 mg ferricarboxymaltose intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrosulfate
Description: 200mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg isotonic sodium and 2 placebo tablets daily
Study: NCT00365053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02245724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Autologous bone marrow mononuclear cell transplantation
Study: NCT01084135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
Study: NCT00881426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets (Sandoz GmbH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
Study: NCT03335241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Pegylated liposomal doxorubicin
Description: Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks
Study: NCT01084135

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
Study: NCT02279589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,5
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,5
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,5
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
Study: NCT04460261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.